BHLH-PAS proteins in cancer

Nature Reviews Cancer

Volumn 13, Issue 12, 2013, Pages 827-841

  Bersten, David C ^a   Sullivan, Adrienne E ^a   Peet, Daniel J ^a   Whitelaw, Murray L ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVITY REGULATED CYTOSKELETON ASSOCIATED PROTEIN; AROMATIC HYDROCARBON RECEPTOR; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CIRCADIAN RHYTHM SIGNALING PROTEIN; CULLIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYTOCHROME P450 1A; FUMARATE HYDRATASE; GLUCOSE 6 PHOSPHATE; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1BETA; ISOCITRATE DEHYDROGENASE 1; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PER ARNT SIM PROTEIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SIRTUIN 1; STAT6 PROTEIN; SUCCINATE DEHYDROGENASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CLOCK; TRYPTOPHAN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ANGIOGENESIS; CARCINOGENESIS; CELL HYPOXIA; CELL INTERACTION; CELL METABOLISM; CELL PROLIFERATION; CIRCADIAN RHYTHM; CONFORMATIONAL TRANSITION; DIMERIZATION; DISEASE ASSOCIATION; DNA BINDING MOTIF; DNA DAMAGE; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GLIOMA; HUMAN; IMMUNOMODULATION; LIGAND BINDING; NEGATIVE FEEDBACK; NEOPLASM; NERVE CELL PLASTICITY; NONHUMAN; OXYGEN SUPPLY; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TRYPTOPHAN METABOLISM; UBIQUITINATION; UPREGULATION; XENOBIOTIC METABOLISM;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL HYPOXIA; CIRCADIAN CLOCKS; CIRCADIAN RHYTHM; CLOCK PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS;

EID: 84888334287     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3621     Document Type: Review

References (181)

1. McIntosh, B. E., Hogenesch, J. B. & Bradfield, C. A. Mammalian Per-Arnt-SIM proteins in environmental adaptation. Annu. Rev. Physiol. 72, 625-645 (2010
2. Michaud, J. L. et al. SIM1 haploinsufficiency causes hyperphagia, obesity and reduction of the paraventricular nucleus of the hypothalamus. Hum. Mol. Genet. 10, 1465-1473 (2001
3. Ramamoorthi, K. et al. Npas4 regulates a transcriptional program in CA3 required for contextual memory formation. Science 334, 1669-1675 (2011
4. Furness, S. G., Lees, M. J. & Whitelaw, M. L. The dioxin (aryl hydrocarbon) receptor as a model for adaptive responses of bHLH/PAS transcription factors. FEBS Lett. 581, 3616-3625 (2007
5. Kewley, R. J., Whitelaw, M. L. & Chapman-Smith, A. The mammalian basic helix-loop-helix/PAS family of transcriptional regulators. Int. J. Biochem. Cell Biol. 36, 189-204 (2004
6. Pongratz, I., Antonsson, C., Whitelaw, M. L. & Poellinger, L. Role of the PAS domain in regulation of dimerization and DNA binding specificity of the dioxin receptor. Mol. Cell. Biol. 18, 4079-4088 (1998
7. Taylor, B. L. & Zhulin, I. B. PAS domains: Internal sensors of oxygen, redox potential, and light. Microbiol. Mol. Biol. Rev. 63, 479-506 (1999
8. Huang, N. et al. Crystal structure of the heterodimeric CLOCK:BMAL1 transcriptional activator complex. Science 337, 189-194 (2012
9. McGuire, J., Okamoto, K., Whitelaw, M. L., Tanaka, H. & Poellinger, L. Definition of a dioxin receptor mutant that is a constitutive activator of transcription: Delineation of overlapping repression and ligand binding functions within the PAS domain. J. Biol. Chem. 276, 41841-41849 (2001
10. To, K. K., Sedelnikova, O. A., Samons, M., Bonner, W. M. & Huang, L. E. The phosphorylation status of PAS-B distinguishes HIF-1α from HIF-2α in NBS1 repression. EMBO J. 25, 4784-4794 (2006
11. Guo, Y. et al. Regulating the ARNT/TACC3 axis: Multiple approaches to manipulating protein/protein interactions with small molecules. ACS Chem. Biol. 8, 626-635 (2013
12. Partch, C. L. & Gardner, K. H. Coactivators necessary for transcriptional output of the hypoxia inducible factor, HIF, are directly recruited by ARNT PAS-B. Proc. Natl Acad. Sci. USA 108, 7739-7744 (2011
13. Okui, M. et al. Transcription factor single-minded 2 (SIM2) is ubiquitinated by the RING-IBR-RING-type E3 ubiquitin ligases. Exp. Cell Res. 309, 220-228 (2005
14. Hao, N., Whitelaw, M. L., Shearwin, K. E., Dodd, I. B. & Chapman-Smith, A. Identification of residues in the N-terminal PAS domains important for dimerization of Arnt and AhR. Nucleic Acids Res. 39, 3695-3709 (2011
15. Beischlag, T. V. et al. Recruitment of the NCoA/SRC-1/ p160 family of transcriptional coactivators by the aryl hydrocarbon receptor/aryl hydrocarbon receptor nuclear translocator complex. Mol. Cell. Biol. 22, 4319-4333 (2002
16. Wang, F., Zhang, R., Wu, X. & Hankinson, O. Roles of coactivators in hypoxic induction of the erythropoietin gene. PLoS ONE 5, e10002 (2010
17. Woods, S. L. & Whitelaw, M. L. Differential activities of murine single minded 1 (SIM1) and SIM2 on a hypoxic response element. Cross-talk between basic helix-loop-helix/per-Arnt-SIM homology transcription factors. J. Biol. Chem. 277, 10236-10243 (2002
18. Ema, M. et al. Two new members of the murine SIM gene family are transcriptional repressors and show different expression patterns during mouse embryogenesis. Mol. Cell. Biol. 16, 5865-5875 (1996
19. Oshima, M., Mimura, J., Sekine, H., Okawa, H. & Fujii-Kuriyama, Y. SUMO modification regulates the transcriptional repressor function of aryl hydrocarbon receptor repressor. J. Biol. Chem. 284, 11017-11026 (2009
20. Denison, M. S., Soshilov, A. A., He, G., DeGroot, D. E. & Zhao, B. Exactly the same but different: Promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor. Toxicol. Sci. 124, 1-22 (2011
21. Hao, N. et al. Xenobiotics and loss of cell adhesion drive distinct transcriptional outcomes by aryl hydrocarbon receptor signaling. Mol. Pharmacol. 82, 1082-1093 (2012
22. Nguyen, L. P. & Bradfield, C. A. The search for endogenous activators of the aryl hydrocarbon receptor. Chem. Res. Toxicol. 21, 102-116 (2008
23. Denissenko, M. F., Pao, A., Tang, M. & Pfeifer, G. P. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 274, 430-432 (1996
24. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013
25. Shimizu, Y. et al. Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc. Natl Acad. Sci. USA 97, 779-782 (2000
26. Opitz, C. A. et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478, 197-203 (2011
27. Andersson, P. et al. A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors. Proc. Natl Acad. Sci. USA 99, 9990-9995 (2002
28. Moennikes, O. et al. A constitutively active dioxin/aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice. Cancer Res. 64, 4707-4710 (2004
29. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012
30. Kawajiri, K. et al. Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in ApcMin/+ mice with natural ligands. Proc. Natl Acad. Sci. USA 106, 13481-13486 (2009
31. Ikuta, T. et al. ASC-associated inflammation promotes cecal tumorigenesis in aryl hydrocarbon receptor-deficient mice. Carcinogenesis 34, 1620-1627 (2013
32. Ohtake, F. et al. Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature 423, 545-550 (2003
33. Ohtake, F. et al. Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature 446, 562-566 (2007
34. Fritz, W. A., Lin, T. M. & Peterson, R. E. The aryl hydrocarbon receptor (AhR) inhibits vanadate-induced vascular endothelial growth factor (VEGF) production in TRAMP prostates. Carcinogenesis 29, 1077-1082 (2008
35. Shin, J. H. et al. Modulation of natural killer cell antitumor activity by the aryl hydrocarbon receptor. Proc. Natl Acad. Sci. USA 110, 12391-12396 (2013
36. Cuzick, J. et al. Selective oestrogen receptor modulators in prevention of breast cancer: An updated meta-analysis of individual participant data. Lancet 381, 1827-1834 (2013
37. Keith, B., Adelman, D. M. & Simon, M. C. Targeted mutation of the murine arylhydrocarbon receptor nuclear translocator 2 (Arnt2) gene reveals partial redundancy with Arnt. Proc. Natl Acad. Sci. USA 98, 6692-6697 (2001
38. Hao, N., Bhakti, V. L., Peet, D. J. & Whitelaw, M. L. Reciprocal regulation of the basic helix-loop-helix/Per- Arnt-SIM partner proteins, Arnt and Arnt2, during neuronal differentiation. Nucleic Acids Res. 41, 5626-5638 (2013
39. Semenza, G. L. Hypoxia-inducible factors in physiology and medicine. Cell 148, 399-408 (2012
40. Bruick, R. K. & McKnight, S. L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337-1340 (2001
41. Epstein, A. C. et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43-54 (2001
42. Ivan, M. et al. HIFα targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 292, 464-468 (2001
43. Jaakkola, P. et al. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468-472 (2001
44. Hewitson, K. S. et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J. Biol. Chem. 277, 26351-26355 (2002
45. Lando, D. et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 16, 1466-1471 (2002
46. Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J. & Whitelaw, M. L. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295, 858-861 (2002
47. Heikkila, M., Pasanen, A., Kivirikko, K. I. & Myllyharju, J. Roles of the human hypoxia-inducible factor (HIF)-3α variants in the hypoxia response. Cell. Mol. Life Sci. 68, 3885-3901 (2011
48. Makino, Y., Kanopka, A., Wilson, W. J., Tanaka, H. & Poellinger, L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3α locus. J. Biol. Chem. 277, 32405-32408 (2002
49. Kaelin, W. G. Jr. Cancer and altered metabolism: Potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. Cold Spring Harb. Symp. Quant. Biol. 76, 335-345 (2011
50. Keith, B., Johnson, R. S. & Simon, M. C. HIF1α and HIF2α: Sibling rivalry in hypoxic tumour growth and progression. Nature Rev. Cancer 12, 9-22 (2012
51. Semenza, G. L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29, 625-634 (2010
52. Uniacke, J. et al. An oxygen-regulated switch in the protein synthesis machinery. Nature 486, 126-129 (2012
53. Kaelin, W. G. Jr & McKnight, S. L. Influence of metabolism on epigenetics and disease. Cell 153, 56-69 (2013
54. King, A., Selak, M. A. & Gottlieb, E. Succinate dehydrogenase and fumarate hydratase: Linking mitochondrial dysfunction and cancer. Oncogene 25, 4675-4682 (2006
55. Pollard, P. J., Wortham, N. C. & Tomlinson, I. P. The TCA cycle and tumorigenesis: The examples of fumarate hydratase and succinate dehydrogenase. Ann. Med. 35, 632-639 (2003
56. Isaacs, J. S. et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability. Cancer Cell 8, 143-153 (2005
57. Koivunen, P. et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483, 484-488 (2012
58. Losman, J. A. & Kaelin, W. G. Jr. What a difference a hydroxyl makes: Mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 27, 836-852 (2013
59. Selak, M. A. et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell 7, 77-85 (2005
60. Zhao, S. et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science 324, 261-265 (2009
61. Sasaki, M. et al. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev. 26, 2038-2049 (2012
62. Sasaki, M. et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488, 656-659 (2012
63. Poon, E., Harris, A. L. & Ashcroft, M. Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev. Mol. Med. 11, e26 (2009
64. Wang, R., Zhou, S. & Li, S. Cancer therapeutic agents targeting hypoxia-inducible factor-1. Curr. Med. Chem. 18, 3168-3189 (2011
65. Erbel, P. J., Card, P. B., Karakuzu, O., Bruick, R. K. & Gardner, K. H. Structural basis for PAS domain heterodimerization in the basic helix-loop-helix-PAS transcription factor hypoxia-inducible factor. Proc. Natl Acad. Sci. USA 100, 15504-15509 (2003
66. Scheuermann, T. H. et al. Artificial ligand binding within the HIF2α PAS-B domain of the HIF2 transcription factor. Proc. Natl Acad. Sci. USA 106, 450-455 (2009
67. Motto, I., Bordogna, A., Soshilov, A. A., Denison, M. S. & Bonati, L. New aryl hydrocarbon receptor homology model targeted to improve docking reliability. J. Chem. Inf. Model. 51, 2868-2881 (2011
68. Scheuermann, T. H. et al. Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nature Chem. Biol. 9, 271-276 (2013
69. Halavaty, A. S. & Moffat, K. N- And C-terminal flanking regions modulate light-induced signal transduction in the LOV2 domain of the blue light sensor phototropin 1 from Avena sativa. Biochemistry 46, 14001-14009 (2007
70. Lee, K. et al. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc. Natl Acad. Sci. USA 106, 17910-17915 (2009
71. Miranda, E. et al. A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. J. Am. Chem. Soc. 135, 10418-10425 (2013
72. Lowrey, P. L. & Takahashi, J. S. Genetics of circadian rhythms in mammalian model organisms. Adv. Genet. 74, 175-230 (2011
73. Kucera, N. et al. Unwinding the differences of the mammalian PERIOD clock proteins from crystal structure to cellular function. Proc. Natl Acad. Sci. USA 109, 3311-3316 (2012
74. Sahar, S. & Sassone-Corsi, P. Metabolism and cancer: The circadian clock connection. Nature Rev. Cancer 9, 886-896 (2009
75. Fu, L. & Lee, C. C. The circadian clock: Pacemaker and tumour suppressor. Nature Rev. Cancer 3, 350-361 (2003
76. Lee, S., Donehower, L. A., Herron, A. J., Moore, D. D. & Fu, L. Disrupting circadian homeostasis of sympathetic signaling promotes tumor development in mice. PLoS ONE 5, e10995 (2010
77. Fu, L., Pelicano, H., Liu, J., Huang, P. & Lee, C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111, 41-50 (2002
78. Gery, S. et al. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol. Cell 22, 375-382 (2006
79. Chen, S. T. et al. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 26, 1241-1246 (2005
80. Hwang-Verslues, W. W. et al. Loss of corepressor PER2 under hypoxia up-regulates OCT1-mediated EMT gene expression and enhances tumor malignancy. Proc. Natl Acad. Sci. USA http://dx.doi.org/10.1073/ pnas.1222684110 (2013
81. Ozturk, N., Lee, J. H., Gaddameedhi, S. & Sancar, A. Loss of cryptochrome reduces cancer risk in p53 mutant mice. Proc. Natl Acad. Sci. USA 106, 2841-2846 (2009
82. Janich, P. et al. The circadian molecular clock creates epidermal stem cell heterogeneity. Nature 480, 209-214 (2011
83. Bass, J. Circadian topology of metabolism. Nature 491, 348-356 (2012
84. Asher, G. & Schibler, U. Crosstalk between components of circadian and metabolic cycles in mammals. Cell. Metab. 13, 125-137 (2011
85. DiTacchio, L. et al. Histone lysine demethylase JARID1a activates CLOCK-BMAL1 and influences the circadian clock. Science 333, 1881-1885 (2011
86. van Zutven, L. J. et al. Identification of NUP98 abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene. Genes Chromosomes Cancer 45, 437-446 (2006
87. Wang, G. G. et al. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature 459, 847-851 (2009
88. Zhou, X. et al. Hypoxia induces trimethylated H3 lysine 4 by inhibition of JARID1A demethylase. Cancer Res. 70, 4214-4221 (2010
89. Chiarugi, A., Dolle, C., Felici, R. & Ziegler, M. The NAD metabolome - A key determinant of cancer cell biology. Nature Rev. Cancer 12, 741-752 (2012
90. Ramsey, K. M. et al. Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. Science 324, 651-654 (2009
91. Nakahata, Y., Sahar, S., Astarita, G., Kaluzova, M. & Sassone-Corsi, P. Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1. Science 324, 654-657 (2009
92. Rutter, J., Reick, M., Wu, L. C. & McKnight, S. L. Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors. Science 293, 510-514 (2001
93. Nakahata, Y. et al. The NAD+-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. Cell 134, 329-340 (2008
94. Asher, G. et al. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. Cell 134, 317-328 (2008
95. Rodgers, J. T. et al. Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1. Nature 434, 113-118 (2005
96. Liu, C., Li, S., Liu, T., Borjigin, J. & Lin, J. D. Transcriptional coactivator PGC-1α integrates the mammalian clock and energy metabolism. Nature 447, 477-481 (2007
97. Hirayama, J. et al. CLOCK-mediated acetylation of BMAL1 controls circadian function. Nature 450, 1086-1090 (2007
98. Doi, M., Hirayama, J. & Sassone-Corsi, P. Circadian regulator CLOCK is a histone acetyltransferase. Cell 125, 497-508 (2006
99. Asher, G. et al. Poly(ADP-ribose) polymerase 1 participates in the phase entrainment of circadian clocks to feeding. Cell 142, 943-953 (2010
100. Geyfman, M. et al. Brain and muscle Arnt-like protein-1 (BMAL1) controls circadian cell proliferation and susceptibility to UVB-induced DNA damage in the epidermis. Proc. Natl Acad. Sci. USA 109, 11758-11763 (2012
101. Kang, T. H., Lindsey-Boltz, L. A., Reardon, J. T. & Sancar, A. Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase. Proc. Natl Acad. Sci. USA 107, 4890-4895 (2010
102. Kang, T. H., Reardon, J. T., Kemp, M. & Sancar, A. Circadian oscillation of nucleotide excision repair in mammalian brain. Proc. Natl Acad. Sci. USA 106, 2864-2867 (2009
103. Lee, J. H. & Sancar, A. Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis. Proc. Natl Acad. Sci. USA 108, 10668-10672 (2011
104. Gorbacheva, V. Y. et al. Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex. Proc. Natl Acad. Sci. USA 102, 3407-3412 (2005
105. Chen, Z., Yoo, S. H. & Takahashi, J. S. Small molecule modifiers of circadian clocks. Cell. Mol. Life Sci. 70, 2985-2998 (2013
106. Chen, Z. et al. Identification of diverse modulators of central and peripheral circadian clocks by high-throughput chemical screening. Proc. Natl Acad. Sci. USA 109, 101-106 (2012
107. Solt, L. A. et al. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature 485, 62-68 (2012
108. Hirota, T. et al. Identification of small molecule activators of cryptochrome. Science 337, 1094-1097 (2012
109. Hirota, T. et al. High-throughput chemical screen identifies a novel potent modulator of cellular circadian rhythms and reveals CKIα as a clock regulatory kinase. PLoS Biol. 8, e1000559 (2010
110. Xu, J., Wu, R. C. & O'Malley, B. W. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nature Rev. Cancer 9, 615-630 (2009
111. Spencer, T. E. et al. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389, 194-198 (1997
112. Chen, H. et al. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90, 569-580 (1997
113. Razeto, A. et al. Structure of the NCoA-1/SRC-1 PAS-B domain bound to the LXXLL motif of the STAT6 transactivation domain. J. Mol. Biol. 336, 319-329 (2004
114. Lodrini, M. et al. P160/SRC/NCoA coactivators form complexes via specific interaction of their PAS-B domain with the CID/AD1 domain. Nucleic Acids Res. 36, 1847-1860 (2008
115. Lee, S. K., Kim, H. J., Kim, J. W. & Lee, J. W. Steroid receptor coactivator-1 and its family members differentially regulate transactivation by the tumor suppressor protein p53. Mol. Endocrinol. 13, 1924-1933 (1999
116. Kim, J. H., Li, H. & Stallcup, M. R. CoCoA, a nuclear receptor coactivator which acts through an N-terminal activation domain of p160 coactivators. Mol. Cell 12, 1537-1549 (2003
117. Kuang, S. Q. et al. AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res. 64, 1875-1885 (2004
118. Belandia, B., Orford, R. L., Hurst, H. C. & Parker, M. G. Targeting of SWI/SNF chromatin remodelling complexes to estrogen-responsive genes. EMBO J. 21, 4094-4103 (2002
119. Johnson, A. B. & O'Malley, B. W. Steroid receptor coactivators 1, 2, and 3: Critical regulators of nuclear receptor activity and steroid receptor modulator (SRM)-based cancer therapy. Mol. Cell Endocrinol. 348, 430-439 (2012
120. Kumar, M. B. & Perdew, G. H. Nuclear receptor coactivator SRC-1 interacts with the Q-rich subdomain of the AhR and modulates its transactivation potential. Gene Expr. 8, 273-286 (1999
121. Carrero, P. et al. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1α. Mol. Cell. Biol. 20, 402-415 (2000
122. Bouras, T., Southey, M. C. & Venter, D. J. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res. 61, 903-907 (2001
123. Fleming, F J. et al. Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1. J. Clin. Pathol. 57, 1069-1074 (2004
124. Kamei, Y. et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85, 403-414 (1996
125. Reiter, R., Wellstein, A. & Riegel, A. T. An isoform of the coactivator AIB1 that increases hormone and growth factor sensitivity is overexpressed in breast cancer. J. Biol. Chem. 276, 9736-39741 (2001
126. Reiter, R., Oh, A. S., Wellstein, A. & Riegel, A. T. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity. Oncogene 23, 403-409 (2004
127. Anzick, S. L. et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277, 965-968 (1997
128. Bautista, S. et al. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin. Cancer Res. 4, 2925-2929 (1998
129. Torres-Arzayus, M. I. et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6, 263-274 (2004
130. Kuang, S. Q. et al. Mice lacking the amplified in breast cancer 1/steroid receptor coactivator-3 are resistant to chemical carcinogen-induced mammary tumorigenesis. Cancer Res. 65, 7993-8002 (2005
131. Fereshteh, M. P. et al. The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice. Cancer Res. 68, 3697-3706 (2008
132. Wang, S. et al. Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation. Proc. Natl Acad. Sci. USA 106, 151-156 (2009
133. Yan, J. et al. Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res. 68, 5460-5468 (2008
134. Berger, M. F. et al. The genomic complexity of primary human prostate cancer. Nature 470, 214-220 (2011
135. Barbieri, C. E. et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature Genet. 44, 685-689 (2012
136. Kan, Z. et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466, 869-873 (2010
137. Geng, C. et al. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc. Natl Acad. Sci. USA 110, 6997-7002 (2013
138. Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22 (2010
139. O'Donnell, K. A. et al. A Sleeping Beauty mutagenesis screen reveals a tumor suppressor role for Ncoa2/ Src-2 in liver cancer. Proc. Natl Acad. Sci. USA 109, E1377-E1386 (2012
140. Carapeti, M., Aguiar, R. C. T., Goldman, J. M. & Cross, N. C. P. A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood 91, 3127-3133 (1998
141. Liang, J., Prouty, L., Williams, B. J., Dayton, M. A. & Blanchard, K. L. Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2. Blood 92, 2118-2122 (1998
142. Deguchi, K. et al. MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. Cancer Cell 3, 259-271 (2003
143. Huntly, B. J. et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6, 587-596 (2004
144. Goshu, E. et al. SIM2 contributes to neuroendocrine hormone gene expression in the anterior hypothalamus. Mol. Endocrinol. 18, 1251-1262 (2004
145. Havis, E. et al. SIM2 prevents entry into the myogenic program by repressing MyoD transcription during limb embryonic myogenesis. Development 139, 1910-1920 (2012
146. Chrast, R. et al. Mice trisomic for a bacterial artificial chromosome with the single-minded 2 gene (SIM2) show phenotypes similar to some of those present in the partial trisomy 16 mouse models of Down syndrome. Hum. Mol. Genet. 9, 1853-1864 (2000
147. DeYoung, M. P., Tress, M. & Narayanan, R. Identification of Down's syndrome critical locus gene SIM2-s as a drug therapy target for solid tumors. Proc. Natl Acad. Sci. USA 100, 4760-4765 (2003
148. Aleman, M. J. et al. Inhibition of Single Minded 2 gene expression mediates tumor-selective apoptosis and differentiation in human colon cancer cells. Proc. Natl Acad. Sci. USA 102, 12765-12770 (2005
149. Laffin, B. et al. Loss of singleminded-2s in the mouse mammary gland induces an epithelial-mesenchymal transition associated with up-regulation of slug and matrix metalloprotease 2. Mol. Cell. Biol. 28, 1936-1946 (2008
150. DeYoung, M. P., Tress, M. & Narayanan, R. Down's syndrome-associated Single Minded 2 gene as a pancreatic cancer drug therapy target. Cancer Lett. 200, 25-31 (2003
151. Halvorsen, O. J. et al. Increased expression of SIM2-s protein is a novel marker of aggressive prostate cancer. Clin. Cancer Res. 13, 892-897 (2007
152. Arredouani, M. S. et al. Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. Clin. Cancer Res. 15, 5794-5802 (2009
153. Long, Q. et al. Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy. Am. J. Pathol. 179, 46-54 (2011
154. Scribner, K. C., Wellberg, E. A., Metz, R. P. & Porter, W. W. Singleminded-2s (SIM2s) promotes delayed involution of the mouse mammary gland through suppression of Stat3 and NFκB. Mol. Endocrinol. 25, 635-644 (2011
155. Scribner, K. C., Behbod, F. & Porter, W. W. Regulation of DCIS to invasive breast cancer progression by Singleminded-2s (SIM2s). Oncogene 32, 2631-2639 (2013
156. Wellberg, E., Metz, R. P., Parker, C. & Porter, W. W. The bHLH/PAS transcription factor singleminded 2s promotes mammary gland lactogenic differentiation. Development 137, 945-952 (2010
157. Vezina, C. M., Lin, T. M. & Peterson, R. E. AHR signaling in prostate growth, morphogenesis, and disease. Biochem. Pharmacol. 77, 566-576 (2009
158. Metz, R. P., Kwak, H. I., Gustafson, T., Laffin, B. & Porter, W. W. Differential transcriptional regulation by mouse single-minded 2s. J. Biol. Chem. 281, 10839-10848 (2006
159. Farrall, A. L. & Whitelaw, M. L. The HIF1α-inducible pro-cell death gene BNIP3 is a novel target of SIM2s repression through cross-talk on the hypoxia response element. Oncogene 28, 3671-3680 (2009
160. Shearman, L. P. et al. Interacting molecular loops in the mammalian circadian clock. Science 288, 1013-1019 (2000
161. Siepka, S. M. et al. Circadian mutant overtime reveals F-box protein FBXL3 regulation of Cryptochrome and Period gene expression. Cell 129, 1011-1023 (2007
162. Yoo, S. H. et al. Competing E3 ubiquitin ligases govern circadian periodicity by degradation of CRY in nucleus and cytoplasm. Cell 152, 1091-1105 (2013
163. Shirogane, T., Jin, J., Ang, X. L. & Harper, J. W. SCFβ- TRCP controls clock-dependent transcription via casein kinase 1-dependent degradation of the mammalian period-1 (Per1) protein. J. Biol. Chem. 280, 26863-26872 (2005
164. Busino, L. et al. SCFFbxl3 controls the oscillation of the circadian clock by directing the degradation of cryptochrome proteins. Science 316, 900-904 (2007
165. Lamia, K. A. et al. AMPK regulates the circadian clock by cryptochrome phosphorylation and degradation. Science 326, 437-440 (2009
166. Lee, C., Etchegaray, J. P., Cagampang, F. R., Loudon, A. S. & Reppert, S. M. Posttranslational mechanisms regulate the mammalian circadian clock. Cell 107, 855-867 (2001
167. Cho, H. et al. Regulation of circadian behaviour and metabolism by REV-ERB-α and REV-ERB-β. Nature 485, 123-127 (2012
168. Preitner, N. et al. The orphan nuclear receptor REV-ERBα controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell 110, 251-260 (2002
169. Sato, T. K. et al. A functional genomics strategy reveals Rora as a component of the mammalian circadian clock. Neuron 43, 527-537 (2004
170. Yin, L. et al. Rev-erbα, a heme sensor that coordinates metabolic and circadian pathways. Science 318, 1786-1789 (2007
171. Hankinson, O. Why does ARNT2 behave differently from ARNT? Toxicol. Sci. 103, 1-3 (2008
172. King, H. A., Hoelz, A., Crane, B. R. & Young, M. W. Structure of an enclosed dimer formed by the Drosophila period protein. J. Mol. Biol. 413, 561-572 (2011
173. Lim, J. H. et al. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1α. Mol. Cell 38, 864-878 (2010
174. Dioum, E. M. et al. Regulation of hypoxia-inducible factor 2α signaling by the stress-responsive deacetylase sirtuin 1. Science 324, 1289-1293 (2009
175. Fan, Y. et al. The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. Cancer Res. 70, 212-220 (2010
176. Liao, D., Corle, C., Seagroves, T. N. & Johnson, R. S. Hypoxia-inducible factor-1α is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res. 67, 563-572 (2007
177. Mazumdar, J. et al. HIF-2α deletion promotes Kras-driven lung tumor development. Proc. Natl Acad. Sci. USA 107, 14182-14187 (2010
178. Doedens, A. L. et al. Macrophage expression of hypoxia-inducible factor-1 α suppresses T-cell function and promotes tumor progression. Cancer Res. 70, 7465-7475 (2010
179. Imtiyaz, H. Z. et al. Hypoxia-inducible factor 2α regulates macrophage function in mouse models of acute and tumor inflammation. J. Clin. Invest. 120, 2699-2714 (2010
180. Wood, P. A. et al. Period 2 mutation accelerates ApcMin/+ tumorigenesis. Mol. Cancer Res. 6, 1786-1793 (2008
181. Chang, H-C. & Guarente, L. SIRT1 mediates central circadian control in the SCN by a mechanism that decays with aging. Cell 153, 1448-1460 (2013